Efferon LPS hemoadsorption medical device designed for extracorporeal blood purification in critical care.
Austria-based Efferon has secured €4.3 million from existing private investors to expand its hemoadsorption medical devices, strengthen distribution and advance clinical and regulatory work.

Efferon, an Austrian medical technology company based in Villach, has raised €4.3 million in seed funding from existing private investors in the DACH region, comprising Germany, Austria and Switzerland. The financing will support the company’s international expansion and further development of its hemoadsorption technology.

Founded in 2016, Efferon is led by co-founder and CEO Dima Romashin and co-founder and CTO Ivan Bessonov. The company develops medical devices designed to remove bacterial endotoxins and excessive inflammatory mediators from the bloodstream, primarily for critical care applications involving sepsis and septic shock.

Its product portfolio includes Efferon LPS, a blood-purification device for adult patients, and Efferon NEO, developed for neonatal and pediatric patients. The devices use hemoadsorption technology to target substances associated with systemic inflammation.

Efferon plans to use the new capital to expand commercial operations across Europe, India and Latin America, strengthen its distributor network, continue regulatory activities and develop additional clinical evidence supporting its technology.

As part of its expansion into India, the company also intends to collect real-world data on the integration of its devices into hospital workflows and the training requirements for medical teams.

According to Efferon, its devices have been used in more than 30,000 treatments. The company reports distribution across 46 countries through a network of 21 distributors.

The latest financing follows a €2.5 million seed round announced in May 2026, which supported European commercial expansion and manufacturing capacity development for its blood-purification devices.

Get the latest startup funding news in your inbox.

We don’t spam! Read our privacy policy for more info.

Share